

# SHREE GANESH BIO-TECH (INDIA) LIMITED

CIN:L70101WB1982PLC121196

Reg. Office: 6TH FLOOR, PREMISES 602, MAHAVIR APARTMENT 2, ASHUTOSH MUKHERJEE ROAD KOLKATA-700020

Email: [shreeganeshbiotechindia@gmail.com](mailto:shreeganeshbiotechindia@gmail.com)

Date: 30.10.2020

To,  
**Listing Department,**  
BSE Limited,  
P J Tower, Dalal Street  
Mumbai-400001

To,  
**The Secretary,**  
The Calcutta Stock  
Exchange Ltd,  
7, Lyons Range,  
Kolkata - 700001

To,  
**Head - Listing**  
Metropolitan Stock Exchange of India  
Limited  
Vibgyor Towers, 4th floor, Plot No C  
62, Opp. Trident Hotel Bandra Kurla  
Complex, Bandra (E), Mumbai –  
400098

Scrip Code: 539470

Scrip Code: 29221

Scrip Code: SHREGANES

Dear Sir/Madam,

**Sub: Outcome of the Board Meeting held on today i.e, 30<sup>th</sup> October 2020.**

**Ref: Regulations 30, 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

We hereby inform you that the Board of Directors of the Company at its meeting held today has:

1. Consider and Approved Un-Audited Financial Result for the Quarter and Half Year ended on 30<sup>th</sup> September 2020.
2. Resignation of Mr. Kalpak Mahendrabhai Vadodaria (DIN: 07664637) from the Directorship of the Company has been accepted with effect from 30.10.2020.

Yours Truly,  
For, SHREE GANESH BIO-TECH (INDIA) LIMITED

DIRECTOR/ AUTHORIZED SIGNATORY



# Shree Ganesh Biotech (India) Ltd

CIN:- L70101WB1982PLC121196

Regd. Office: 6th Floor, Premises - 602, Mahavir Apartment, 2, Ashutosh Mukherjee Road, Kolkata - 700020

Email:- shreeganeshbiotechindia@gmail.com

## Statement of Audited Financial Results for the Quarter & Half Year Ended September 30, 2020

Sl no.	Particulars	Quarter Ended			Six Months Ended		(Rs. In lacs)
		30-Sep-20	30-Jun-20	30-Sep-19	30-Sep-20	30-Sep-19	Year Ended 31 Mar 2020
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1</b>	<b>INCOME</b>						
(a)	Revenue From Operation	-	11.35	119.00	11.35	223.85	247.30
(b)	Other Income	-	-	-	-	-	-
	<b>Total Income from Operations (Net)</b>	<b>-</b>	<b>11.35</b>	<b>119.00</b>	<b>11.35</b>	<b>223.85</b>	<b>247.30</b>
<b>2</b>	<b>EXPENSES</b>						
(a)	Cost of material consumed	-	7.70	77.00	7.70	141.80	157.53
(b)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	-	-	-	-	-	-
(c)	Employee benefit expense	0.95	0.99	4.39	1.94	5.64	6.42
(d)	Finance Costs	-	-	-	-	-	0.05
(e)	Depreciation and amortization expense	-	-	-	-	-	0.11
(f)	Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	2.58	7.08	26.59	9.66	51.08	59.61
	<b>Total Expenses</b>	<b>3.53</b>	<b>15.77</b>	<b>107.98</b>	<b>19.30</b>	<b>198.52</b>	<b>223.72</b>
<b>3</b>	<b>Profit / (Loss) from operations before exceptional items Tax (1-2)</b>	<b>(3.53)</b>	<b>(4.42)</b>	<b>11.02</b>	<b>(7.95)</b>	<b>25.33</b>	<b>23.58</b>
<b>4</b>	<b>Exceptional Items</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>5</b>	<b>Profit / (Loss) before Tax (3 ± 4)</b>	<b>(3.53)</b>	<b>(4.42)</b>	<b>11.02</b>	<b>(7.95)</b>	<b>25.33</b>	<b>23.58</b>
<b>6</b>	<b>Tax Expense</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>7</b>	<b>Net Profit / (Loss) after Tax (5 - 6)</b>	<b>(3.53)</b>	<b>(4.42)</b>	<b>11.02</b>	<b>(7.95)</b>	<b>25.33</b>	<b>23.58</b>
<b>8</b>	<b>Other Comprehensive Income (net of tax)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>9</b>	<b>Total Comprehensive Income for the period (7 ± 8)</b>	<b>(3.53)</b>	<b>(4.42)</b>	<b>11.02</b>	<b>(7.95)</b>	<b>25.33</b>	<b>23.58</b>
<b>10</b>	<b>Paid-up equity share capital (Face Value of Rs.10/- each)</b>	<b>1,993.12</b>	<b>1,993.12</b>	<b>1,993.12</b>	<b>1,993.12</b>	<b>1,993.12</b>	<b>1,993.12</b>
<b>11</b>	<b>Other Equity</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>3,754.42</b>
<b>12</b>	<b>Earnings Per Share (of Rs. 10/- each) (not annualised):</b>						
	(a) Basic	(0.02)	(0.02)	0.06	(0.04)	0.13	0.12
	(b) Diluted	(0.02)	(0.02)	0.06	(0.04)	0.13	0.12



# Shree Ganesh Biotech (India) Ltd

CIN:- L70101WB1982PLC121196

Regd. Office: 6th Floor, Premises - 602, Mahavir Apartment, 2, Ashutosh Mukherjee Road, Kolkata - 700020

Email:- shreeganeshbiotechindiaLtd@gmail.com

(Rs. in Lakhs)

Standalone Statement of Assets and Liabilities		As at 30th September, 2020	As at 31st March, 2020
Particulars		Un-Audited	Audited
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current assets</b>		
	Property, plant and equipment	0.46	0.46
	Capital work-in-progress	-	-
	Other intangible assets	-	-
	Investments in subsidiaries, associates and joint ventures	-	-
	<b>Financial assets</b>		
	Investments	-	-
	Loans	4,384.67	4,386.00
	Other financial assets	-	-
	Income Tax assets (net)	-	-
	Deferred tax assets (net)	-	-
	Other non-current assets	-	-
	<b>Sub-total - Non-Current Assets</b>	<b>4,385.13</b>	<b>4,386.46</b>
<b>2</b>	<b>Current assets</b>		
	Inventories	-	-
	<b>Financial assets</b>		
	Investments	-	-
	Trade receivables	2,084.98	2,079.19
	Cash and cash equivalents	0.86	1.38
	Bank balances other than Cash and Cash equivalents above	0.41	0.41
	Loans, Current	-	-
	Other financial assets	-	-
	Other current assets	4.17	4.17
	Assets classified as held for sale	-	-
	<b>Sub-total - Current Assets</b>	<b>2,090.42</b>	<b>2,085.15</b>
	<b>TOTAL - ASSETS</b>	<b>6,475.55</b>	<b>6,471.61</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity</b>		
	Equity Share capital	1,993.12	1,993.12
	Other equity	3,746.46	3,754.41
	<b>Sub-total - Shareholders' funds</b>	<b>5,739.58</b>	<b>5,747.53</b>
<b>2</b>	<b>LIABILITIES</b>		
	<b>Non-current liabilities</b>		
	<b>Financial liabilities</b>		
	Borrowings, non-Current	19.03	19.03
	Provisions	-	-
	Income tax liabilities (net)	-	-
	Other non-current liabilities	-	-
	<b>Sub-total - Non-current liabilities</b>	<b>19.03</b>	<b>19.03</b>
<b>3</b>	<b>Current liabilities</b>		
	<b>Financial liabilities</b>		
	Borrowings, Current	-	-
	Trade payables, Current	717.19	705.30
	Other financial liabilities	-	-
	Other current liabilities	(0.25)	(0.25)
	Provisions	-	-
	Current tax liabilities (net)	-	-
	<b>Sub-total - Current liabilities</b>	<b>716.94</b>	<b>705.05</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>6,475.55</b>	<b>6,471.61</b>



# Shree Ganesh Biotech (India) Ltd

CIN:- L70101WB1982PLC121196

Regd. Office: 6th Floor, Premises - 602, Mahavir Apartment, 2, Ashutosh Mukherjee Road, Kolkata - 700020

Email:- shreeganeshbiotechindiaLtd@gmail.com

## Notes:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on October 30, 2020.
- 2 The Statutory Auditors have carried out a limited review of the above financial result.
- 3 Company has only one segment and hence no separate segment result has been given.
- 4 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- 5 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015  
Management has made an assessment of the impact of COVID 19 in preparation for these financial results. Management has considered all relevant external and internal factors in the measurement of assets and liabilities including recoverability of carrying values of its assets, its liquidity position and ability to repay debts. No adjustment to key estimates and judgements that impact the financial results have been
- 6 identified. However, the impact assessment of COVID19 will be a continuing process given the uncertainties associated with its nature and duration and no significant impact is envisaged on the operations.

By order of the Board  
For, Shree Ganesh Biotech (India) Ltd

Director/Compliance Officer

Place : Kolkata

Date : 30th October, 2020

**Shree Ganesh Biotech (India) Ltd**

CIN:- L70101WB1982PLC121196

Regd. Office: 6th Floor, Premises - 602, Mahavir Apartment, 2, Anhutosh Mukherjee Road, Kolkata - 700020

**STANDALONE STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED 30 SEPTEMBER 2020**

(Rs. in Lakhs, unless otherwise stated)

Particulars	30.09.2020	30.09.2019
	Rupees	Rupees
<b>A. CASH FLOW FROM OPERATING ACTIVITIES:</b>		
Profit before tax	7.95	25.33
Adjustment For :		
Share of (profit)/loss from investment in partnership firm	-	-
Depreciation/amortization on continuing operation	-	-
Interest expenses	-	-
<b>Operating profit before working capital changes</b>	<b>7.95</b>	<b>25.33</b>
<b>Movement in Working Capital :</b>		
Increase/(decrease) in Inventory	-	-
Increase/(decrease) in Trade receivables	5.79	179.01
Increase/(decrease) in Short Term Loan & Advances	-	-
Increase/(decrease) in Current Liabilities	-	-
Increase/(decrease) in Trade Payable	11.89	133.81
Increase/(decrease) in Other Current Assets	-	-
Direct taxes paid (net of refunds)	-	-
<b>Net Cash Flow from Operating Activities(A)</b>	<b>1.85</b>	<b>19.87</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>		
Investments / withdrawal in Partnership Firm	-	-
Purchase / Sale of Fixed Assets	-	-
Increase/(decrease) in Long Term Loan & Advances	1.33	17.27
<b>Net Cash Flow from Investing Activities(B)</b>	<b>1.33</b>	<b>17.27</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceed (Repayment) from long term borrowing	-	-
Proceed (Repayment) from short term borrowing	-	-
Proceed from Preferential Warrants	-	-
<b>Net Cash Flow from Financing Activities(C)</b>	<b>-</b>	<b>-</b>
<b>Net increase/(decrease) in cash &amp; cash equivalents(A+B+C)</b>	<b>0.52</b>	<b>2.60</b>
Cash and Cash equivalents (Opening Balance)	1.79	3.96
<b>Cash and Cash equivalents (Closing Balance)</b>	<b>1.27</b>	<b>1.36</b>

Previous year figure have been regrouped/ reclassified wherever necessary

As per our report of even date

For, BIPIN & CO.

Chartered Accountants

FRN: 101509 W

CA ANUJ SHAIK

Partner

M. No.: 126337

Place: VADODARA

Date: 30th October, 2020

For and on Behalf of the Board



Director

Place: KOLKATA

Date: 30th October, 2020



# BIPIN & CO.

## CHARTERED ACCOUNTANTS



### INDEPENDENT AUDITORS' REVIEW REPORT ON THE STANDALONE UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2020


To  
The Board of Directors of  
**Shree Ganesh Biotech (India) Ltd**

We have reviewed the unaudited financial results of **Shree Ganesh Biotech (India) Ltd** (the "Company") for the quarter and the half year ended September 30, 2020 which are included in the accompanying Standalone Financial Results, Standalone Balance Sheet as on that date and the Standalone Statement of Cash Flows for the half-year ended on that date (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies and has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For, BIPIN & CO.**  
**Chartered Accountants**  
**FRN: 101509 W**

  
**CA AMIT SHAH**  
**Partner**  
**M. No.: 126337**  
**UDIN: 20126337AAAADK7998**

**Place: Vadodara**  
**Date: 30.10.2020**

CA Bipin Shah ☎ 94264 86830 | CA Tejas Purohit ☎ 98257 68699 | CA Dhavit Shah ☎ 94273 41134 | CA Amit Shah ☎ 9426313900  
CA Dhruv Agrawal ☎ 9824015889 | CA Pradeep Agrawal ☎ 98985 60967 | CA Suresh Sisodia ☎ 9825156037.

📍 302/412, Centre Point, R.C. Dutt Road, Alkapuri, Vadodara - 390 007 ☎ 0265-2338665 / 2323577

✉ bipin.co@gmail.com, bipin.smdt@gmail.com 🌐 www.cabipinco.com

**(NETWORK & ASSOCIATE OFFICES ACROSS INDIA)**